Immunoreactive Trypsinogen (IRT) Cutoffs and Follow-Up in Newborn Screening
An elevated IRT on newborn screening is defined variably by state programs, with absolute cutoffs ranging from 90-105 ng/mL or relative cutoffs at the top 4-10% of daily/monthly values, and requires immediate follow-up with either repeat IRT testing at 2 weeks or DNA analysis for CFTR mutations on the same blood spot. 1
Understanding IRT Cutoff Approaches
The definition of "abnormal" IRT varies significantly across screening programs because different laboratory kits produce varying IRT distributions. Programs use two main approaches:
Absolute Cutoffs
- Range: 90-105 ng/mL used by five states (Colorado, Connecticut, Montana, New Jersey, Wyoming) 1
- Fixed values provide consistency but may miss seasonal variations
Percentile-Based Cutoffs
- Top 4-5% of daily/monthly values: Used by Connecticut, Massachusetts, New York, Wisconsin 1
- Top 10% of daily values: Used by Mississippi and Pennsylvania 1
- Floating cutoffs are generally superior because IRT levels vary by season and reagent lot number, affecting assay sensitivity 2
Critical Follow-Up Algorithms
When IRT is elevated, two validated pathways exist:
IRT/Repeat IRT Protocol
- Obtain second dried blood spot at approximately 2 weeks of age 1
- IRT values decrease with age in infants without CF, improving specificity
- If repeat IRT remains elevated → refer for sweat chloride testing
- Sweat chloride >60 mEq/L (confirmed by second test) is diagnostic 1
IRT/DNA Protocol (Higher Sensitivity)
- Perform DNA analysis on same blood spot for CFTR mutations 1
- IRT/DNA with 23-mutation panel achieves 96.2% sensitivity vs. 80.2% for IRT/IRT 2
- If elevated IRT + ≥1 mutation detected → refer directly to CF diagnostic center for sweat testing
- Children with two disease-causing mutations have CF regardless of sweat test results 1
Important Clinical Caveats
Borderline sweat chloride values (30-59 mEq/L) are ambiguous—infants may have classic CF, atypical CF, or no CF 1. These require ongoing monitoring and genetic counseling.
Extremely high IRT without detected mutations: Additional testing has extremely low yield regardless of how elevated the IRT value is 3. However, programs using IRT/DNA often include a protocol to refer infants with markedly elevated IRT but no identified mutation directly for sweat testing 1.
False-negative rates: IRT/IRT screening misses 10-20% of CF cases 2, while IRT/DNA with multiple-mutation panels achieves >98% sensitivity 1. Infants with meconium ileus may have low IRT values and be missed by screening but are detected clinically 1.
Factors affecting IRT levels that can complicate interpretation:
- Gestational age <42 weeks increases false-positive risk 4
- Low birth weight infants have significantly higher IRT values 2
- Seasonal variation and reagent lot changes affect mean and 95th percentile values 2
- Maternal factors: higher gravity, smoking exposure, chronic diseases associated with elevated IRT 4
Racial and Ethnic Disparities
Minoritized populations have higher rates of missed and delayed diagnoses—Black and Hispanic infants have 2.7-fold and 6.1-fold higher odds respectively of missed or delayed diagnosis compared to non-Hispanic White infants 5. This reflects both lower mutation detection rates with standard panels and systemic barriers to follow-up sweat testing.
Timing Imperatives
Median age at diagnosis via screening is 0.5 months compared to 14.5 months for symptom-based diagnosis 1. Diagnosis based on symptoms is associated with >2-fold greater risk of medical complications before diagnosis 1. Every delay matters for preventing irreversible lung damage and optimizing nutritional status.